Table 1 Base case results by health states
Base Case Results | Dabrafenib / Trametinib | Observation |
|---|---|---|
Life Years, discounted (rate: 3%) | ||
Relapse Free Survival | 10.13 | 6.77 |
Locoregional progression | 0.75 | 0.80 |
Distant metastasis | 1.32 | 2.23 |
Total LY | 12.20 | 9.80 |
QALY, discounted (rate: 3%) | ||
Relapse Free Survival | 8.79 | 5.88 |
Locoregional progression | 0.66 | 0.70 |
Distant metastasis | 0.89 | 1.51 |
Total QALY | 10.34 | 8.09 |
Lifetime costs (T€, discounted by 3%) | ||
Treatment | 112.1 | – |
Relapse Free Survival | 3.4 | 2.5 |
Locoregional progression | 0.2 | 0.23 |
Distant metastasis | 39.4 | 66.3 |
Total | 155.1 | 69.0 |